Amgen (AMGN) PT Raised to $195 at Barclays
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- SanDisk upgraded at JPMorgan after investor day; shares climb
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Amgen Announces Succession Plans For Two Executive Officers
July 26, 2018 4:02 PM EDTTHOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ -- As part of Amgen's (NASDAQ: AMGN) planned executive succession to address upcoming retirements, the Company announced transition plans for two of its executive vice presidents today.
After more than 21 years of leadership in the biopharmaceutical industry, including the past 16 years with Amgen, Sean E. Harper, M.D., executive vice president of Research and Development, has decided to retire and plans to pursue opportunities in the early-stage biotechnology community. David M. Reese, M.D., currently senior vice president of Translational Sciences and Oncology... More
Amgen Reports Second Quarter 2018 Financial Results
July 26, 2018 4:01 PM EDTTHOUSAND OAKS, Calif., July 26, 2018 /PRNewswire/ --Â Amgen (NASDAQ: AMGN) today announced financial results for the second quarter of 2018. Key results include:
Total revenues increased 4 percent versus the second quarter of 2017 to $6.1 billion. Product sales grew 2 percent globally. New and recently launched products including Repatha® (evolocumab), KYPROLIS® (carfilzomib), Prolia® (denosumab) and XGEVA® (denosumab), showed double-digit growth. GAAP earnings per share (EPS) increased 20 percent to $3.48 driven by higher product sales, a lower tax rate and lower weighted-average shares outstanding. GAAP operating income increased 5... More